Cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
 
(8 intermediate revisions by the same user not shown)
Line 28: Line 28:


==Guidelines==
==Guidelines==
----
[[Cardiomyopathy 2023 ESC Guideline Recommendations|2023 ESC Guideline Recommendations]] | [[Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy|2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy]]
=== <b><font color="red"> 2023 ESC Guideline Recommendations </font> </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657  }} </ref>===
 
====<u> Recommendations for the Provision of Service of [[Multidisciplinary]] [[Cardiomyopathy]] Teams </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. It is recommended that all [[patients]] with [[cardiomyopathy]] and their relatives have access to multidisciplinary teams with expertise in the [[diagnosis]] and [[management]] of [[cardiomyopathies]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| bgcolor="LightGray"|2. Timely and adequate preparation for transition of [[care]] from [[pediatric]] to [[adult]] services, including [[joint]] [[consultations]], is recommended in all [[adolescents]] with [[cardiomyopathy]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|}
 
====<u> Recommendations for [[Diagnostic]] [[Work-up]] in [[Cardiomyopathies]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. It is recommended that all [[patients]] with suspected or established [[cardiomyopathy]] undergo [[systematic]] evaluation using a multiparametric approach that includes [[clinical]] evaluation, [[pedigree]] analysis, [[ECG]], [[Holter monitoring]], [[laboratory]] tests, and [[multimodality]] [[imaging]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| bgcolor="LightGray"|2. It is recommended that all [[patients]] with suspected [[cardiomyopathy]] undergo evaluation of [[family history]] and that a three- to four-[[generation]] [[family tree]] is created to aid in [[diagnosis]], provide clues to underlying [[etiology]], determine [[inheritance]] pattern, and identify at- [[risk]] [[relatives]]
|bgcolor= "LightBlue"; style="text-align:center;|C
|}
 
====<u> Recommendations for [[Laboratory Tests]] in the [[Diagnosis]] of [[Cardiomyopathies]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. Routine (first-level) [[laboratory]] tests are recommended in all [[patients]] with suspected or confirmed [[cardiomyopathy]] to evaluate [[etiology]], assess [[disease]] [[severity]], and aid in detection of extra-[[cardiac]] [[manifestations]] and assessment of secondary [[organ]] [[dysfunction]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|}
 
====<u> Recommendations for [[Echocardiographic]] [[Evaluation]] in [[Patients]] with [[Cardiomyopathies]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. A comprehensive evaluation of [[cardiac]] dimensions and [[LV]] and [[RV]] [[systolic]] (global and regional) and [[LV]] [[diastolic]] function is recommended in all [[patients]] with [[cardiomyopathy]] at initial evaluation, and during follow-up, to monitor [[disease]] progression and aid [[risk stratification]] and [[management]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|}
 
====<u> Recommendations for [[Cardiac]] [[Magnetic Resonance]] Indication in [[Patients]] with [[Cardiomyopathies]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. [[Contrast]]-enhanced [[CMR]] is recommended in [[patients]] with [[cardiomyopathy]] at initial evaluation.
|bgcolor= "Turquoise"; style="text-align:center; |B
|}
 
====<u> Recommendations for [[Computed Tomography]] and [[Nuclear Imaging]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. [[DPD]]/[[PYP]]/[[HMDP]] [[bone-tracer scintigraphy]] is recommended in [[patients]] with suspected [[ATTR]]-related [[cardiac]] [[amyloidosis]] to aid [[diagnosis]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|}
 
====<u> Recommendations for [[Genetic Counselling]] and Testing in [[Cardiomyopathies]] </u>====
 
{|class="wikitable" style="width:80%"
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Genetic Counselling]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
|bgcolor="LightGray"|1. [[Genetic]] [[counselling]], provided by an appropriately trained [[healthcare]] [[professional]] and including [[genetic]] education to inform decision-making and [[psychosocial support]], is recommended for [[families]] with an [[inherited]] or suspected [[inherited]] [[cardiomyopathy]], regardless of whether [[genetic testing]] is being considered.
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
|bgcolor="LightGray"|2. It is recommended that [[genetic testing]] for [[cardiomyopathy]] is performed with access to a [[multidisciplinary]] team, including those with
expertise in [[genetic testing]] [[methodology]], sequence variant interpretation, and [[clinical]] application of [[genetic testing]], typically in a specialized
[[cardiomyopathy]] service or in a network model with access to equivalent expertise.
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
|bgcolor="LightGray"|3. Pre- and post-test [[genetic]] [[counselling]] is recommended in all [[individuals]] undergoing [[genetic testing]] for [[cardiomyopathy]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>Index [[Patients]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1.[[Genetic testing]] is recommended in [[patients]] fulfilling [[diagnostic]] criteria for [[cardiomyopathy]] in cases where it enables [[diagnosis]],
[[prognostication]]], [[therapeutic]] stratification, or [[reproductive]] [[management]] of the [[patient]], or where it enables cascade [[genetic]] evaluation of their [[relatives]] who would otherwise be enrolled into long-term surveillance.
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| bgcolor="LightGray"|2. [[Genetic testing]] is recommended for a [[deceased]] [[individual]] identified to have [[cardiomyopathy]] at [[post-mortem]] if a [[genetic]] [[diagnosis]] would facilitate [[management]] of surviving [[relatives]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Family Members]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. It is recommended that cascade [[genetic testing]], with pre- and post-test [[counselling]], is offered to [[adult]] at-risk [[relatives]] if a confident [[genetic]] [[diagnosis]] (i.e. a P/LP variant) has been established in an [[individual]] with [[cardiomyopathy]] in the [[family]] (starting with first-degree [[relatives]] if available, and cascading out sequentially).
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
|colspan="1" style="text-align:center; background:LightCoral"| [[ESC #Classification of Recommendations|Class III]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|2. [[Diagnostic]] [[genetic testing]] is not recommended in a [[phenotype]]-negative [[relative]] of a [[patient]] with [[cardiomyopathy]] in the absence of a confident [[genetic]] [[diagnosis]] (i.e. a P/LP variant) in the [[family]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|}
 
====<u> Recommendations for [[Cardiac]] [[Implantation]] in [[Patients]] with [[Cardiomyopathy]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. [[Orthotopic cardiac transplantation]] is recommended for eligible [[cardiomyopathy]] [[patients]] with advanced [[heart failure]] ([[NYHA class III–IV]]) or intractable [[ventricular arrhythmia]] refractory to [[medical]]/[[invasive]]/[[device therapy]], and who do not have absolute [[contraindications]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| bgcolor="LightGray"|2. It is recommended that all [[patients]] with suspected [[cardiomyopathy]] undergo evaluation of [[family history]] and that a three- to four-[[generation]] [[family tree]] is created to aid in [[diagnosis]], provide clues to underlying [[etiology]], determine [[inheritance]] pattern, and identify at- [[risk]] [[relatives]]
|bgcolor= "LightBlue"; style="text-align:center;|C
|}
 
====<u> Recommendations for [[Management]] of [[Atrial Fibrillation]] and [[Atrial Flutter]] in [[Patients]] with [[Cardiomyopathy]] </u>====
 
{|class="wikitable" style="width:80%"
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Anticoagulation]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
|bgcolor="LightGray"|1. [[Oral anticoagulation]] in order to reduce the risk of [[stroke]] and [[thromboembolic]] events is recommended in all [[patients]] with [[HCM]] or [[cardiac]] [[amyloidosis]] and [[AF]] or [[atrial flutter]] (unless contraindicated).
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
|bgcolor="LightGray"|2. [[Oral anticoagulation]] to reduce the risk of [[stroke]] and [[thromboembolic]] events is recommended in [[patients]] with [[DCM]], [[NDLVC]], or [[ARVC]], and [[AF]] or [[atrial flutter]] with a [[CHA2DS2-VASc score]] ≥2 in [[men]] or ≥3 in [[women]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b> Control of [[symptoms]] and [[heart failure]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1.[[Atrial fibrillation]] [[catheter ablation]] is recommended for[[ rhythm control]] after one failed or intolerant [[class I]] or [[III]] [[AAD]] to improve [[symptoms]] of [[AF]] recurrences in [[patients]] with [[paroxysmal]] or persistent [[AF]] and [[cardiomyopathy]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| bgcolor="LightGray"|2. [[Atrial fibrillation]] [[catheter ablation]] is recommended to reverse [[LV dysfunction]] in [[AF]] [[patients]] with [[cardiomyopathy]] when a
[[tachycardia]]-induced component is highly probable, independent of their [[symptom]] status.
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Comorbidities]] and associated [[risk factor]] [[management]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. Modification of an un[[healthy]] [[lifestyle]] and targeted [[therapy]] of intercurrent conditions is recommended to reduce [[AF]] burden and [[symptom]] severity in [[patients]] with [[cardiomyopathy]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|}
 
====<u> Recommendations for [[Implantable Cardioverter Defibrillator]] in [[Patients]] with [[Cardiomyopathy]] </u>====
 
{|class="wikitable" style="width:80%"
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>General Recommendations</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
|bgcolor="LightGray"|1. [[Implantation]] of a [[cardioverter defibrillator]] is only recommended in [[patients]] who have an expectation of good quality[[ survival]] >1 year.
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
|bgcolor="LightGray"|2. It is recommended that ICD implantation be guided by shared decision-making that:
*Is [[evidence-based]];
*Considers a [[person]]’s [[individual]] preferences, beliefs, circumstances, and values; and
*Ensures that the [[person]] understands the benefits, [[harm]], and possible consequences of different [[treatment]] options
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| bgcolor="LightGray"|3. It is recommended that prior to [[ICD]] [[implantation]], [[patients]] are counselled on the [[risk]] of inappropriate [[shocks]], [[implant]] [[complications]], and the social, occupational, and driving implications of the [[device]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
|colspan="1" style="text-align:center; background:LightCoral"| [[ESC #Classification of Recommendations|Class III]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|4. It is not recommended to [[implant]] an [[ICD]] in [[patients]] with incessant [[ventricular arrhythmias]] until the [[ventricular arrhythmia]] is controlled.
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Secondary Prevention]]</b>
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Implantation]] of an [[ICD]] is recommended:</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
|bgcolor="LightGray"|
* In [[patients]] with [[HCM]], [[DCM]], and [[ARVC]] who have survived a [[cardiac arrest]] due to [[VT]] or [[VF]], or who have spontaneous sustained [[ventricular arrhythmia]] causing [[syncope]] or [[hemodynamic]] compromise in the absence of reversible causes.
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
|bgcolor="LightGray"|
* In [[patients]] with [[NDLVC]] and [[RCM]] who have survived a [[cardiac arrest]] due to [[VT]] or [[VF]], or who have spontaneous sustained [[ventricular arrhythmia]] causing [[syncope]] or [[hemodynamic]] compromise in the absence of reversible causes.
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>[[Primary Prevention]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
|bgcolor="LightGray"|1. Comprehensive [[SCD]] [[risk stratification]] is recommended in all [[cardiomyopathy]] [[patients]] who have not suffered a previous [[cardiac arrest]]/ [[sustained ventricular arrhythmia]] at initial evaluation and at 1–2 year intervals, or whenever there is a change in [[clinical status]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
|bgcolor="LightGray"|2. The use of validated [[SCD]] [[algorithms]]/scores as aids to the shared decision-making when offering [[ICD implantation]], where available is recommended in [[patients]] with [[HCM]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| colspan="2" style="text-align:center; background:WhiteSmoke" | <b>Choice of [[ICD]]</b>
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
|bgcolor="LightGray"|1. When an [[ICD]] is indicated, it is recommended to evaluate whether the [[patient]] could benefit from [[CRT]].
|bgcolor= "CadetBlue"; style="text-align:center;|A
|}
 
====<u> Recommendations for Routine Follow-up of [[Patients]] with [[Cardiomyopathy]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. It is recommended that all [[clinically-stable]] [[patients]] with [[cardiomyopathy]] undergo routine [[follow-up]] using a multi-parametric approach that includes [[ECG]] and [[echocardiography]] every 1–2 years.
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| bgcolor="LightGray"|2. [[Clinical evaluation]] with [[ECG]] and [[multimodality]] [[imaging]] is recommended in [[patients]] with [[cardiomyopathy]] whenever there is a substantial or unexpected change in [[symptoms]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|}
 
====<u> Recommendations for [[Family]] [[Screening]] and [[Follow-up]] Evaluation of [[Relatives]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. Following cascade [[genetic testing]], [[clinical evaluation]] using a multi-parametric approach that includes [[ECG]] and [[cardiac imaging]] and long-term [[follow-up]] is recommended in [[first-degree relatives]] who have the same [[disease]]-causing [[variant]] as the [[proband]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| bgcolor="LightGray"|2. Following cascade [[genetic testing]], it is recommended that [[first-degree relatives]] without a [[phenotype]] who do not have the same
[[disease]]-causing [[variant]] as the [[proband]] are discharged from further [[follow-up]] but advised to seek [[re-assessment]] if they develop [[symptoms]] or when new [[clinical]]ly relevant data emerge in the [[family]].
|bgcolor= "LightBlue"; style="text-align:center;|C
|-
| bgcolor="LightGray"|3. It is recommended that when no [[P/LP]] [[variant]] is identified in the [[proband]] or [[genetic testing]] is not performed, an initial [[clinical evaluation]] using a multi-parametric approach that includes [[ECG]] and [[cardiac imaging]] is performed in [[first-degree relatives]].
|bgcolor= "LightBlue"; style="text-align:center;|C
 
|}
 
====<u> Recommendations for [[Psychological]] Support in [[Patients]] and [[Family]] Members with [[Cardiomyopathies]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. It is recommended that [[psychological]] support by an appropriately trained [[health professional]] be offered to all [[individuals]] who have experienced the premature [[sudden cardiac death]] of a [[family member]] with [[cardiomyopathy]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| bgcolor="LightGray"|2. It is recommended that [[psychological support]] by an appropriately trained [[health professional]] be offered to all [[individuals]] with an [[inherited]] [[cardiomyopathy]] who receive an [[implantable cardioverter defibrillator]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|}
 
====<u> Recommendation for Evaluation of [[Left Ventricular Outflow Tract Obstruction]] </u>====
 
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
|colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
|-
| bgcolor="LightGray"|1. In all [[patients]] with [[HCM]], at initial evaluation, [[transthoracic]] [[2D]] and [[Doppler echocardiography]] are recommended, at rest and during [[Valsalva maneuver]] in the sitting and semi-[[supine]] positions — and then on standing if no gradient is provoked—to detect [[LVOTO]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|-
| bgcolor="LightGray"|2. In [[symptomatic]] [[patients]] with [[HCM]] and a resting or provoked peak instantaneous [[LV outflow tract]] gradient <50 mmHg, [[2D]] and [[Doppler echocardiography]] during [[exercise]] in the standing, sitting (when possible), or semi-[[supine]] position are recommended to detect provocable [[LVOTO]] and [[exercise]]-induced [[mitral regurgitation]].
|bgcolor= "Turquoise"; style="text-align:center;|B
|}
----
----
 
=== <b><font color="red">  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy</font> </b> <ref name="pmid33215931">{{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volume= 142 | issue= 25 | pages= e558-e631 | pmid=33215931 | doi=10.1161/CIR.0000000000000937 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33215931  }} </ref>===


== Case Studies ==
== Case Studies ==

Latest revision as of 07:04, 13 November 2023

Cardiomyopathy
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy

CDC on Cardiomyopathy

Cardiomyopathy in the news

Blogs on Cardiomyopathy

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub,MD; Mahshid Mir, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3], Raviteja Guddeti, M.B.B.S. [4]; Edzel Lorraine Co, DMD, MD[5]


Synonyms and keywords: Myocardiopathy; cardiac muscle disease; heart muscle disease.

Overview

Historical Perspective

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations | 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

de:Kardiomyopathie nl:Cardiomyopathie no:Kardiomyopati simple:Cardiomyopathy sr:Кардиомиопатија sv:Hjärtmuskelsjukdom

Template:WikiDoc Sources

References